Loretta Itri

Experienced Pharmaceutical Industry Executive Dr. Loretta Itri

About Loretta Itri

As chief medical officer and president of pharmaceutical development at a public biotech company, Dr. Loretta Itri oversaw the worldwide development of a number of important drugs, including Tesetaxel, a novel oral taxane used in the treatment of breast, gastric, and prostate cancer. Previously, Dr. Loretta Itri served as a senior vice president of worldwide affairs at Ortho Biotech, a Johnson & Johnson company, in Raritan, New Jersey, and as an assistant vice president in charge of clinical oncology development at Hoffmann La Roche, Inc., in Nutley, New Jersey. Dr. Itri has also served on the board of directors for the American-Italian Cancer Foundation.

After earning her medical degree from New York Medical College in Valhalla, Dr. Loretta Itri served a residency in Internal Medicine at the State University of New York at Stony Brook and a fellowship in medical oncology at the Memorial Sloan-Kettering Cancer Center in Manhattan. Over the course of her career, Dr. Itri has published more than 130 clinical abstracts, articles, and book chapters.